Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa trial of AGS 004 for long-term viral control in paediatric patients with HIV infection

Next Previous
Trial Profile

Phase IIa trial of AGS 004 for long-term viral control in paediatric patients with HIV infection

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AGS 004 (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 30 Mar 2015 Planned initiation date changed from 1 Dec 2014 to 1 Dec 2015. According to an Argos Therapeutics media release, this trial planned for second half of 2015.
    • 23 May 2014 New trial record
    • 13 May 2014 Argos Therapeutics intends to devote its cash, cash equivalents and short term investments to fund certain of the costs of the planned phase 2 clinical trial of AGS 004 for long-term viral control in paediatric patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top